Wellnex Life Limited (Wellnex, WNX or Company) (ASX:WNX), owner and developer of some of Australia's leading health brands, has recently published key ASX announcements.
Share Consolidation and ASX Code
Announcement Highlights
- Wellnex Life Limited (ASX: WNX) advises that on 26 September 2024, shareholders of the Company approved the consolidation of the Company’s issued capital on a fifty for one (50:1) basis. The last day for trading on a pre-consolidation basis was 8 October 2024.
- In accordance with the timetable announced to the ASX on 28 August 2024, trading in the Company’s securities take place from today on a post-consolidation and deferred settlement basis.
- The Company’s ASX code will be ‘WNXDA’ on the ASX platform whilst trading is on a deferred settlement basis. Normal trading commences on Monday, 18 October 2024 under ASX code ‘WNX’.
Read the full Wellnex Life Half-Year Report & Trading Update here.
Completion of Share Consolidation
Announcement Highlights
- Wellnex Life Limited (ASX: WNX) advises that the consolidation of share capital on a fifty (50) for one (1) basis as approved by shareholders at the Annual General Meeting held on 26 September 2024 is now complete.
- In addition, the Company’s current Convertible Note on issue had a conversion price of $0.08 (refer to the Company’s Notice of Annual General Meeting (Resolution 4) released to the ASX on 16 November 2023). This conversion price will be adjusted to $4.0 post consolidation in accordance with the terms of the Convertible Note. No other changes to the terms of the Convertible Note.
- New holding statements are being dispatched to shareholders on a post-consolidation basis.
- Normal trading commences on Friday, 18 October 2024 under ASX code ‘WNX’.
Read the full Wellnex Life Company Update here.
To learn more about Wellnex Life and stay up to date with investor information, subscribe to the Company's Chairman’s List.
